March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has entered into a strategic partnership with Tanner Pharma Group to make eRapa available for Familial Adenomatous Polyposis (FAP) patients via an Early A ...

March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has entered into a strategic partnership with Tanner Pharma Group to make eRapa available for Familial Adenomatous Polyposis (FAP) patients via an Early A ...

March 9, 2026 Biodexa Announces Support for Life’s a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life's a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization's vital work empowering ...

Core Viewpoint - MTX240's unique mechanism may provide a significant advantage in treating gastrointestinal stromal tumors (GIST), particularly for patients resistant to current therapies [1][2]. Group 1: Company Overview - Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare diseases, with a growing emphasis on gastrointestinal cancers [1]. - The company has introduced MTX240, a new candidate targeting GIST, which is now phase 1-ready [1]. Group 2: Mechanism of Action - MTX240 employs a unique molecular glue mechanism that distinguishes it from existing treatments, potentially benefiting a wider range of GIST patients, including those with TKI-resistant disease [2]. - Unlike TKIs that often fail due to tumor cell mutations, MTX240 is designed to remain effective regardless of secondary mutations in GIST [3]. Group 3: Preclinical Success - In preclinical PDX models, MTX240 showed dose-dependent efficacy in reducing GIST tumors, both in non-resistant and TKI-resistant cases [4]. - If clinical trials confirm these preclinical results, MTX240 could be co-administered with TKIs or even replace them entirely [5]. Group 4: Regulatory and Market Potential - MTX240 is eligible for Orphan Drug designation in the U.S. and EU, granting it market exclusivity for seven and ten years, respectively, upon approval [5]. - The drug has Composition of Matter patents extending through 2037, enhancing its market potential [5]. Group 5: Licensing and Financial Aspects - Biodexa has secured exclusive worldwide rights to MTX240, excluding Japan, with a modest upfront fee and development milestones included in the licensing deal [6]. - The agreement also involves low double-digit approval milestones and mid single-digit tiered royalties [6].

Core Viewpoint - Biodexa Pharmaceuticals has secured an exclusive license for OPB-171775, a novel molecular glue aimed at treating gastrointestinal stromal tumors (GIST), which is expected to address significant unmet medical needs in patients resistant to current therapies [1][12]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for rare diseases with unmet medical needs [14]. - The company is advancing a pipeline that includes eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, alongside MTX240 [14][16]. Product Details - MTX240, also known as OPB-171775, utilizes a unique molecular glue mechanism to induce targeted protein interactions, distinguishing it from conventional kinase inhibitors [3]. - The compound targets GIST by stabilizing SLFN12, which promotes apoptosis in cancer cells through a pathway independent of KIT signaling, potentially overcoming resistance mechanisms associated with existing therapies [5]. Clinical Rationale - GIST is primarily driven by mutations in the KIT receptor tyrosine kinase, with current treatments often leading to resistance due to secondary mutations or alternative signaling pathways [4]. - Approximately 10-15% of GIST patients are either primarily refractory or develop secondary resistance to available TKIs, highlighting the need for new therapeutic options [10]. Efficacy Evidence - In patient-derived xenograft (PDX) models, MTX240 demonstrated dose-dependent anti-tumor efficacy in TKI-resistant scenarios, regardless of KIT mutation status [6][9]. - The PDX models used in studies are more predictive of human clinical outcomes, bridging laboratory findings with potential clinical applications [9]. Market Potential - The global GIST market is valued at approximately USD 1.3 billion, with an expected annual growth rate of 6-10% through 2032, driven by increasing incidence and new treatment options for resistant cases [11]. - GIST qualifies for orphan drug designation, which may provide regulatory advantages and incentives for drug development [11]. Licensing Agreement - Under the licensing agreement, Biodexa holds exclusive rights to develop and commercialize MTX240 globally, except in Japan, where Otsuka retains rights [12]. - The agreement includes an upfront fee, development milestones, and tiered royalties on net sales in the mid-single digit range [12]. Intellectual Property - MTX240 is protected by composition of matter patents in the US, Europe, Japan, and other countries, extending through 2037 without any patent term extension [13].

Core Viewpoint - Biodexa Pharmaceuticals has secured an exclusive license for OPB-171775, a novel molecular glue aimed at treating gastrointestinal stromal tumors (GIST), which may also have applications in other indications [1][2]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for rare diseases with unmet medical needs [1][13]. - The company is advancing its pipeline, which includes MTX240 (OPB-171775) and eRapa, targeting conditions such as Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer [2][13]. Product Details - MTX240 utilizes a unique molecular glue mechanism that facilitates targeted protein interactions, distinguishing it from conventional kinase inhibitors [3]. - The compound targets GIST driven by mutations in the KIT receptor tyrosine kinase, addressing the challenge of resistance that often develops with existing tyrosine kinase inhibitors (TKIs) [4][5]. Clinical Rationale - MTX240 has demonstrated dose-dependent anti-tumor efficacy in patient-derived xenograft (PDX) models resistant to imatinib and sunitinib, regardless of KIT mutation status [6][8]. - The mechanism of action involves stabilizing SLFN12 to induce apoptosis in GIST cells through a pathway independent of KIT signaling, potentially benefiting a significant proportion of GIST patients [5][9]. Market Opportunity - GIST affects approximately 3,000-4,000 patients annually in the U.S., with 10-15% of patients experiencing resistance to available TKIs, highlighting a substantial unmet medical need [9]. - The global GIST market is valued at around USD 1.3 billion and is projected to grow at an annual rate of 6-10% through 2032, driven by increasing incidence and new therapeutic options [10]. Licensing Agreement - Biodexa has exclusive global rights to develop and commercialize MTX240, except in Japan where Otsuka retains rights. The agreement includes an upfront fee, development milestones, and tiered royalties on net sales [11]. Intellectual Property - MTX240 is protected by composition of matter patents in the U.S., Europe, Japan, and other countries, extending through 2037 without any patent term extension [12].

Group 1 - Biodexa Pharmaceuticals has promoted Fiona Sharp to CFO and Company Secretary, effective immediately [1] - Fiona Sharp joined the company as Group Financial Controller in December 2019 and has expanded her responsibilities to include many CFO duties [1] - Stephen Stamp will step down from his roles as CFO and Company Secretary but will continue to serve as CEO [1]

Core Viewpoint - Biodexa Pharmaceuticals PLC has appointed Fiona Sharp as Chief Financial Officer and Company Secretary, promoting her to the Board of Directors, effective immediately [2][4]. Group 1: Leadership Changes - Fiona Sharp has been with Biodexa since December 2019, initially serving as Group Financial Controller, and has expanded her responsibilities to include many CFO duties [3]. - Stephen Stamp will step down from his roles as CFO and Company Secretary but will continue as Chief Executive Officer [4]. Group 2: Company Background - Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [5]. - The company's lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [5]. Group 3: Product Development - eRapa is an oral capsule formulation of rapamycin, an mTOR inhibitor that plays a significant role in cellular metabolism and tumorigenesis [6]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential as a first-in-class blood glucose modulating agent [6]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier to reduce systemic toxicity [7]. Group 4: Company Capabilities - Biodexa is supported by three proprietary drug delivery technologies aimed at enhancing the bio-delivery and bio-distribution of medicines [8].

Core Viewpoint - Biodexa Pharmaceuticals PLC has announced a public offering priced at $10 million, aimed at funding its development programs and general corporate purposes [2][3]. Offering Details - The offering consists of 157,000 ADS Units, each comprising one American depositary share (representing 100,000 ordinary shares) and two Series L warrants [2]. - Additionally, there are 2,891,781 Pre-Funded Units, each consisting of one pre-funded warrant to purchase one ADS and two Series L Warrants [2]. - The public offering price for each ADS Unit is set at $3.28, while each Pre-Funded Unit is priced at $3.2799 [2]. Financial Proceeds - The expected gross proceeds from the offering, before deducting fees and expenses, are approximately $10 million [3]. - The net proceeds will be utilized for development programs, working capital, and other corporate purposes [3]. Closing and Agent Information - The offering is anticipated to close on December 19, 2025, pending customary closing conditions [4]. - Maxim Group LLC is acting as the sole placement agent for this offering [4]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [7]. - The company's lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [7]. Product Details - eRapa is an oral formulation of rapamycin, an mTOR inhibitor involved in cellular metabolism and tumorigenesis [8]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential for glycaemic control in diabetes [9]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier [10][11].

Market Overview - US stock futures showed modest gains with Dow futures up about 0.07% to 48,514, S&P 500 futures gaining roughly 0.13% to 6,865, and Nasdaq futures rising 0.15% to around 25,419, reflecting a market balancing softer economic signals with hopes of nearing the end of the Fed's tightening cycle [1][17] - The previous regular session ended mixed, with the Dow falling 0.62% and S&P 500 slipping 0.24%, extending their losing streaks to three days, while the Nasdaq Composite managed a 0.23% gain [2][17] Economic Data - The US economy lost 105,000 jobs in October, raising the unemployment rate to 4.6%, the highest since September 2021, but November saw a rebound with payrolls increasing by 64,000 jobs, exceeding the Dow Jones estimate of 45,000 [4][17] - Despite the rebound, hiring remains below earlier levels, keeping investors cautious about potential economic momentum loss [7][17] Federal Reserve and Interest Rates - Investors are closely monitoring comments from Federal Reserve officials Christopher Waller and John Williams for insights on future rate moves and interpretations of the recent unemployment rise [8][17] - The 10-year Treasury yield is around 4.15%, which continues to pressure equity valuations, especially in rate-sensitive sectors [9][17] Corporate News - Micron Technology and General Mills are notable companies reporting earnings, with Micron's price target raised to $300 due to strong AI-driven demand, forecasting over 25% upside [17] - Tesla is facing regulatory scrutiny after a California judge ruled it could face a 30-day suspension of licenses related to its Autopilot and Full Self-Driving marketing [17] - Amazon is reportedly in talks to invest about $10 billion in OpenAI, potentially intensifying competition in the AI sector [17] Pre-market Activity - AMC Robotics surged nearly 66% on heavy volume, Rezolve AI jumped over 27%, and Biodexa Pharmaceuticals also saw strong gains, while Tesla slipped amid regulatory headlines and Nvidia was slightly lower ahead of earnings [10][15][17] Global Market Trends - Asia-Pacific markets traded mostly higher, with Hong Kong's Hang Seng up 0.82%, China's Shanghai Composite and Shenzhen Component rising 1.19% and 1.70%, respectively, and Japan's Nikkei adding 0.26% [13][17] - European markets opened mostly higher ahead of key central bank decisions and fresh inflation data from the UK, providing additional context for US investors [14][17]